secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2024-03-04T23:59:59+00:00
Accession:  0001193125-24-058031
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon holds virtual R&D Day focusing on Guillain-Barré Syndrome program
-------------------------------------------------------------------------

- Presentation highlighted serious unmet need in Guillain-Barré Syndrome and Annexon's novel therapeutic approach.
- Webcast archive available on investor page for 30 days; CEO Douglas Love presented.
- No financial results, guidance, or clinical data disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312524058031/0001193125-24-058031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312524058031/d790221d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-058031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer